Movement Alert｜Sanofi Falls 3.19% in Regular Trading, Phase III Trial Failure of Key Pipeline Drug Continues to Weigh on Shares

Market Focus06-22

On June 22, Sanofi fell 3.19% in regular trading, trading at $40.96/share, with turnover of approximately $19.65 million. The decline extends selling pressure following the company's announcement on June 10 that it would terminate the Phase III MOBILIZE study of its core pipeline asset riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).

An independent data monitoring committee's interim analysis indicated the study was unlikely to meet its pre-specified efficacy endpoints. Riliprubart, a humanized IgG4 monoclonal antibody and selective C1s inhibitor, had been projected to achieve peak sales of 2 to 5 billion euros, making it one of Sanofi's most critical growth drivers. The trial failure has disrupted the company's strategy of relying on new product launches to sustain revenue growth as its blockbuster drug Dupixent faces patent cliff pressures. The compounding uncertainty around Sanofi's pipeline continues to weigh on investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104293211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104293211","market":"us","top_or_hot":-1,"title":"Movement Alert｜Sanofi Falls 3.19% in Regular Trading, Phase III Trial Failure of Key Pipeline Drug Continues to Weigh on Shares","media":"Market Focus","content":"<p><p>On June 22, Sanofi fell 3.19% in regular trading, trading at $40.96/share, with turnover of approximately $19.65 million. The decline extends selling pressure following the company's announcement on June 10 that it would terminate the Phase III MOBILIZE study of its core pipeline asset riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).</p><p>An independent data monitoring committee's interim analysis indicated the study was unlikely to meet its pre-specified efficacy endpoints. Riliprubart, a humanized IgG4 monoclonal antibody and selective C1s inhibitor, had been projected to achieve peak sales of 2 to 5 billion euros, making it one of Sanofi's most critical growth drivers. The trial failure has disrupted the company's strategy of relying on new product launches to sustain revenue growth as its blockbuster drug Dupixent faces patent cliff pressures. The compounding uncertainty around Sanofi's pipeline continues to weigh on investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sanofi Falls 3.19% in Regular Trading, Phase III Trial Failure of Key Pipeline Drug Continues to Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sanofi Falls 3.19% in Regular Trading, Phase III Trial Failure of Key Pipeline Drug Continues to Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-22 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 22, Sanofi fell 3.19% in regular trading, trading at $40.96/share, with turnover of approximately $19.65 million. The decline extends selling pressure following the company's announcement on June 10 that it would terminate the Phase III MOBILIZE study of its core pipeline asset riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).</p><p>An independent data monitoring committee's interim analysis indicated the study was unlikely to meet its pre-specified efficacy endpoints. Riliprubart, a humanized IgG4 monoclonal antibody and selective C1s inhibitor, had been projected to achieve peak sales of 2 to 5 billion euros, making it one of Sanofi's most critical growth drivers. The trial failure has disrupted the company's strategy of relying on new product launches to sustain revenue growth as its blockbuster drug Dupixent faces patent cliff pressures. The compounding uncertainty around Sanofi's pipeline continues to weigh on investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"","article_id":"1104293211","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104293211","pubTimestamp":1782135998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 22, Sanofi fell 3.19% in regular trading, trading at $40.96/share, with turnover of approximately $19.65 million. The decline extends selling pressure following the company's announcement on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特"},"translate_title":"动静提示|赛诺菲常规交易跌3.19%关键管线药物III期试验失败继续打压股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1},"content_text":"On June 22, Sanofi fell 3.19% in regular trading, trading at $40.96/share, with turnover of approximately $19.65 million. The decline extends selling pressure following the company's announcement on June 10 that it would terminate the Phase III MOBILIZE study of its core pipeline asset riliprubart for refractory chronic inflammatory demyelinating polyneuropathy (CIDP).An independent data monitoring committee's interim analysis indicated the study was unlikely to meet its pre-specified efficacy endpoints. Riliprubart, a humanized IgG4 monoclonal antibody and selective C1s inhibitor, had been projected to achieve peak sales of 2 to 5 billion euros, making it one of Sanofi's most critical growth drivers. The trial failure has disrupted the company's strategy of relying on new product launches to sustain revenue growth as its blockbuster drug Dupixent faces patent cliff pressures. The compounding uncertainty around Sanofi's pipeline continues to weigh on investor sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104293211","isCrawlerRequest":true}